neurolymphomatosis
Jump to navigation
Jump to search
Etiology
Epidemiology
- rare
Pathology
- lymphomatous infiltration of peripheral nerves
- peripheral nerves (60%)
- spinal nerve roots (48%)
- cranial nerves (46%)
- plexus (40%)
- multiple site involvement (58%)
Clinical manifestations
- progressive peripheral neuropathy (sensory & motor)
Diagnostic procedures
- nerve biopsy confirms diagnosis (88%)
Radiology
- magnetic resonance imaging (77% positive)
- PET scan (84% positive)
Management
- response to treatment in 46%
- systemic chemotherapy (70%)
- intrathecal chemotherapy (49%)
- radiotherapy (34%)
- prognosis
- median overall survival 10 months
- 12-month survival 46%
- 36-month survival 24%
More general terms
References
- ↑ Gan HK, Azad A, Cher L, Mitchell PL. Neurolymphomatosis: diagnosis, management, and outcomes in patients treated with rituximab. Neuro Oncol. 2010 Feb;12(2):212-5. Epub 2009 Dec 24. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20150388 Free PMC Article
- ↑ Grisariu S, Avni B, Batchelor TT et al Neurolymphomatosis: an International Primary CNS Lymphoma Collaborative Group report. Blood. 2010 Jun 17;115(24):5005-11. Epub 2010 Apr 5. PMID: https://www.ncbi.nlm.nih.gov/pubmed/20368468 Free PMC Article
- ↑ 3.0 3.1 David WS, Bowley MP, Mehan WA et al Case 19-2017 - A 53-Year-Old Woman with Leg Numbness and Weakness. N Engl J Med 2017; 376:2471-2481. June 22, 2017 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28636859 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMcpc1701762
- ↑ Rush RP, Saltman AP, Prica AA, Breiner A, Detsky AS. Connecting the Dots. N Engl J Med. 2017 Sep 7;377(10):978-984. <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28877025 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMcps1613804